17. The Use of Plasma-Derived Concentrates

  1. Augusto B. Federici MD3,
  2. Christine A. Lee MA, MD, DSc (Med), FRCP, FRCPath, FRCOGad eundem4,
  3. Erik E. Berntorp MD, PhD5,
  4. David Lillicrap MD6 and
  5. Robert R. Montgomery MD7,8
  1. Pier Mannuccio Mannucci MD1 and
  2. Massimo Franchini MD2

Published Online: 21 MAR 2011

DOI: 10.1002/9781444329926.ch17

Von Willebrand Disease: Basic and Clinical Aspects

Von Willebrand Disease: Basic and Clinical Aspects

How to Cite

Mannucci, P. M. and Franchini, M. (2011) The Use of Plasma-Derived Concentrates, in Von Willebrand Disease: Basic and Clinical Aspects (eds A. B. Federici, C. A. Lee, E. E. Berntorp, D. Lillicrap and R. R. Montgomery), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444329926.ch17

Editor Information

  1. 3

    Division of Hematology and Transfusion Medicine, L. Sacco University Hospital, Department of Internal Medicine, University of Milan, Milan, Italy

  2. 4

    University of London, London, UK

  3. 5

    Malmö Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden

  4. 6

    Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Kingston, ON, Canada

  5. 7

    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA

  6. 8

    Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI, USA

Author Information

  1. 1

    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Medicine and Medical Specialties, University of Milan and IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy

  2. 2

    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Italy

Publication History

  1. Published Online: 21 MAR 2011
  2. Published Print: 25 MAR 2011

ISBN Information

Print ISBN: 9781405195126

Online ISBN: 9781444329926



  • von Willebrand disease;
  • von Willebrand factor;
  • factor VIII;
  • VWF/FVIII concentrates;
  • bleeding;
  • thrombosis;
  • therapy


von Willebrand disease (VWD) is the most common hereditary bleeding disorder that affects both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes mucous membrane and soft-tissue bleeding. The aim of treatment is to correct the dual defect of hemostasis caused by the abnormal/reduced VWF and the concomitant secondary deficiency of factor VIII (FVIII). Desmopressin (DDAVP) is the treatment of choice for patients with type 1 VWD who have FVIII and VWF levels of 10 IU/dL or more, while plasma-derived VWF concentrates, either containing FVIII or devoid of this moiety, are indicated for those who are unresponsive or insufficiently responsive to DDAVP (severe type 1, type 2, and type 3 VWD).